Astrazeneca PLC (AZN): Price and Financial Metrics

Astrazeneca PLC (AZN)

Today's Latest Price: $54.72 USD

0.44 (-0.80%)

Updated Jun 2 4:00pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • AZN has a higher market value than 98.99% of US stocks; more precisely, its current market capitalization is $143,526,320,000.
  • With a price/earnings ratio of 116.97, Astrazeneca Plc P/E ratio is greater than that of about 95.01% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, AZN is more volatile than just 4.14% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Astrazeneca Plc, a group of peers worth examining would be AMGN, LLY, SAP, NVO, and TMO.
  • AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to
AZN Daily Price Range
AZN 52-Week Price Range

AZN Stock Price Chart More Charts

AZN Price/Volume Stats

Current price $54.72 52-week high $57.44
Prev. close $55.16 52-week low $36.15
Day low $54.10 Volume 4,274,260
Day high $54.74 Avg. volume 4,424,063
50-day MA $49.71 Dividend yield 3.37%
200-day MA $47.51 Market Cap 143.61B

Astrazeneca PLC (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 19th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Astrazeneca Plc, consider:

  • The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.12%; that's greater than only 15.12% of US stocks we're applying DCF forecasting to.
  • Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 62.88% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See PRGO, CPIX, RMD, ARA, and NRC.

AZN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

FDA OKs expanded use of AstraZeneca's Brilinta

The FDA approves AstraZeneca's (AZN) blood thinner Brilinta (ticagrelor), combined with aspirin, for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.The med was first approved in the U.S. in July 2011 for acute coronary syndrome....

Seeking Alpha | June 1, 2020

AstraZeneca's heart drug gets FDA nod

AstraZeneca Plc said on Monday the U.S. Food and Drug Administration has approved its drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.

Reuters | June 1, 2020

INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines

The first wave of the COVID-19 pandemic may be waning. Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates may be at such low levels that there is not enough disease circulating to truly test potential vaccines.

Yahoo | June 1, 2020

AstraZeneca scores twin drug approvals alongside vaccine progress

AstraZeneca, now the most valuable London-listed company, has received international attention thanks to its hot pursuit of a coronavirus vaccine. It sealed U.S. government funding last month and aims to produce a billion doses this and next year. But while the recent buzz around the British firm has focused on a vaccine, cancer and heart medications are still its core business. On Monday (June 1) AstraZeneca clinched expanded regulatory backing for two medications, including one for major cancer treatment Lynparza. A panel of the European health regulator gave it the go ahead for use on a form of advanced pancreatic cancer. Also on Monday, the company got a green light from the U.S. for a heart medication. Meanwhile, AstraZeneca's covid vaccine manufacturing partner Oxford Biomedica l...

Yahoo | June 1, 2020

Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer

FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.

Yahoo | June 1, 2020

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 5.51%
3-mo 12.59%
6-mo 17.20%
1-year 48.75%
3-year 73.20%
5-year 99.72%
YTD 11.94%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8248 seconds.